A Randomized, Double-blind, Placebo Controlled, Cross-over Clinical Trial of Acute Safety and Biological Effects of a Polyphenol Supplement
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Blood levels of CD38
研究概览
简要总结
A randomized, double-blind, placebo controlled, cross-over trial to investigate the effect of the Investigational Product "DailyColors™" (DC) on age-related pathways in adults.
The aim of this study is to measure the effects of acute treatment with DC on key pathways relevant to healthy ageing using blood biomarkers.
Based on power calculations a sample size of 20, is sufficient to detect an effect size of 0.46 at a power > 90%. To account for dropout the investigators will include 26 subjects in total.
详细描述
Aims:
The aim of this study is to measure the effects of acute treatment with DC on key pathways relevant to healthy ageing using blood biomarkers.
Hypotheses:
There will be preliminary evidence that the IP has positive clinical effects on biologically relevant pathways related to healthy aging of brain and muscle including blood markers of inflammation, oxidative stress markers, and trophic factors.
Design:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
A randomized, double-blind, placebo controlled, cross-over trial to investigate the effect of the Investigational Product (DailyColors™) on age-related pathways in adults. Participants will receive DailyColors™ or placebo for a week, then one week wash-out, and then placebo/Dailycolors™ for a week, in random order. In addition, participants will be asked for consent to be contacted for participation in an open-label extension study for 3 months at a later date.
入排标准
- 年龄范围
- 55 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female, (NB Equal number of male and female participants)
- •Age between 55 and 80
- •Body Mass Index (BMI) over 25 (since this group is expected to have a some degree of inflammation and other metabolic changes and more likely to respond to the supplement)
- •Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits
- •Provided voluntary, written, informed consent to participate in the study.
排除标准
- •Alcohol or drug abuse in past year
- •Subject has a known allergy to the test material's active or inactive ingredients
- •Subjects with unstable, life-threatening medical conditions
- •Use of polyphenol or phytochemical supplements
- •Use of dietary supplements last month, except from cod liver oil or other vitamin D supplements
- •Vegetarians and Vegans
- •Clinically significant abnormal laboratory results at screening
- •Participation in a clinical research trial within 30 days prior to randomization
- •Individuals with dementia and/or who are unable to give informed consent
- •Individuals with unusual high intake of fruit, berries, vegetable and/ or coffee intake, > 5 portions of fruit, berries and/or vegetables per day or > 5 cups of coffee per day
- •Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.
结局指标
主要结局
Blood levels of CD38
时间窗: 3 weeks
Change from baseline in the blood levels of CD38 at 1hour, 2 hours, 24 hours and week 1 and week 3. Blood CD38 is measured using commercially available immunoassays.
Blood levels of NAD+
时间窗: 3 weeks
Change from baseline in the blood levels of NAD+ at 1hour, 2 hours, 24 hours and week 1 and 3. Blood NAD+ is measured using commercially available assay kits.
次要结局
- Blood levels of 4-HNE(3 weeks)
- Blood levels of protein carbonyl(3 weeks)
- Blood levels of biomarkers for inflammation(3 weeks)
- Blood-based measurement of total antioxidant capacity(3 weeks)